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Background
Risperidone is the only atypical drug available as a depot
or long-acting injectable formulation. Long-acting intra-
muscular risperidone injection (RLAI) is a formulation
that combines the benefits of atypical antipsychotics with
improvements in compliance associated with depot for-
mulations.
Materials and methods
We systematically followed-up 33 (24 male and 9 female)
-according to DSM-IV- schizophrenic patients (para-
noid:20, disorganized:10 and undifferentiated type:3),
with average age 39.54 years (26-55) and average duration
of illness 14.96 years (5-26), for more than 18 months.
Patients demonstrated a variety of reasons for receiving a
long-acting injectable antipsychotic drug, including a his-
tory of non-compliance (57%), insufficient control of
symptoms with previous atypical antipsychotics (28%),
and adverse events with other treatments (15%). 21
(64%) patients were hospitalized when RLAI was initi-
ated. The average dose of RLAI was 50.75mg every two
weeks. Antipsychotic, anticholinergic or benzodiazepines
coprescription was infrequent.
Results
After more than 18 months of treatment (average dura-
tion of follow-up: 25.125 months) many patients (73%)
show significant and sustained clinical improvement in
their symptoms over their original condition (CGI and
BPRS score) and had no relapse or admission during this
period despite their history of frequent exacerbations of
symptoms and many hospitalizations. Treatment was
well tolerated as demonstrated through the adverse event
profile.
Conclusions
Long-acting risperidone injection seems to be an impor-
tant advance in the management of patients requiring
continuous antipsychotic therapy for long-term mainte-
nance treatment. It seems to have the potential to extend
benefits of assured medication delivery and improved
long-term outcomes. Initiating it during inpatient treat-
ment may be an important strategy in improving long-
term outcomes among patients with schizophrenia.
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